Mylan launches generic Invega

PITTSBURGH — Mylan on Monday announced that it had launched its generic version of Janseen’s Invega (paliperidone) extended-release  tablets following final Food and Drug Administration approval.

The tablets will be sold in 1.5-, 3-, 6- and 9-mg dosage strengths. Paliperidone is meant to treat patients with schizophrenia in adults and adolescents (12-17 years of age) and schizoaffectifve disorder.

Invega sales for the 12 months ended June 30 were $606.2 million.